Case Discussion 1: Targeting Antigens in AML—New Advances in Antibody–Drug Conjugate and Other Antibody-Based Therapies
Case Discussion 2: Overcoming Treatment Challenges in Patients With Newly Diagnosed AML
Case Discussion 3: Available and Emerging Treatment Options in FLT3-Mutant AML
Case Discussion 4: Available and Emerging Treatment Options in IDH-Mutant AML
Exploring New Therapeutic Frontiers in AML—What Are the Emerging Molecular Targets?
Closing Remarks and Question and Answer Session
Date / Time
San Diego, CA
Marriott Marquis San Diego Hotel Marina
Farhad Ravandi, MD
Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Mark J. Levis, MD, PhD
Professor of Oncology
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Gary J. Schiller, MD
Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California
Eunice S. Wang, MD
Chief, Leukemia Service
Department of Medicine
Roswell Park Cancer Institute
Buffalo, New York
Using an interactive, case-based approach, this live expert-led program will focus on the dramatic and rapid changes in AML treatment, including state-of-the-art testing and therapeutics for newly diagnosed AML, advances in antibody–drug conjugates, treatment options for FLT3- or IDH-mutant AML, and exploration of novel AML agents in clinical trial.
The goal of this activity is to improve the competence and performance of the multidisciplinary care team in applying the latest practice-changing developments to the clinical care of patients with acute myeloid leukemia.
This program is intended for physicians and other healthcare providers who care for patients with acute myeloid leukemia
- Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, and therapeutic decisions
- Assess the available evidence to optimally integrate antibody–drug conjugates and other antibody-based therapies in AML
- Plan evidence-based therapeutic strategies using novel formulations and refinements of conventional chemotherapy
- Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations
- Manage treatment-related toxicities associated with novel therapeutics
- Identify patients with AML who may benefit from enrollment on clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.